MedAI Verdict
All comparisons

aetherAI vs Tempus Digital Pathology

aetherAI fits hospital labs that run the Philips Ultra Fast Scanner and the Philips PS27QHDCR monitor. Its single FDA record, K233126 from May 2024, covers the aetherSlide viewer for primary diagnosis of FFPE surgical pathology slides on that hardware only. The vendor lists bone marrow and colon polyp modules with Taiwan TFDA approval.

Tempus suits a hospital lab that wants Paige's FDA-authorized prostate tool beside its own viewer, and its page says Prostate Detect must be used with specific scanners and viewers. The line holds two FullFocus viewer 510(k)s, K201005 from July 2020 and K241273 from January 2025, plus Paige Prostate Detect, a De Novo authorization (DEN200080, September 2021) with CE-IVDR marking and a vendor-claimed 20% shorter reading time. aetherAI is the weaker buy for a hospital lab that wants an FDA-authorized AI tool beside its viewer, since the K233126 indication carries no AI claim. Paige Predict and the Breast, Lymph Node, GI and PanCancer Detect tools are labeled research use only.

Pathology · Reviewed November 2, 2026

aetherAI logo

aetherAI

by aetherAI · founded 2015

FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.

Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.

When to pick each one

aetherAI

  • Cleared viewer for primary diagnosis, K233126
  • Cleared with Philips scanner and monitor
  • Bone marrow and polyp modules approved by TFDA
Read the full aetherAI review

Tempus Digital Pathology

  • Paige FullFocus viewer 510(k)s plus Prostate Detect De Novo
  • Prostate Detect also carries CE-IVDR
  • Vendor claims 20% shorter reading time
Read the full Tempus Digital Pathology review

Score

Each row shows points earned of points available under the published rubric.

aetherAI

51of 100

Solid choice

Tempus Digital Pathology

38of 100

Competitive
Score by dimension for aetherAI and Tempus Digital Pathology
DimensionaetherAITempus Digital PathologyDifference
FDA clearance18 / 1818 / 180
HIPAA / SOC2 / BAA0 / 100 / 100
EHR integrations (count)0 / 4.20 / 4.20
Top-3 EHR coverage (Epic / Oracle / Athena)0 / 2.40 / 2.40
Peer-reviewed papers14.7 / 210 / 21+14.7
RCT / meta-analysis / systematic review0 / 7.80 / 7.80
Funding & adoption signal3 / 1212 / 12-9
Pricing transparency2.5 / 52.5 / 50
Years in market6 / 60 / 6+6

Scroll horizontally to see every column.

How scores are computed

Pricing

aetherAI

TierMonthlyAnnualNotes
Enterprisen/an/aNo public price.

Tempus Digital Pathology

TierMonthlyAnnualNotes
Enterprisen/an/aNo public price on the Tempus pages.

Compliance and integrations

Documented from each vendor’s own pages.

SpecaetherAITempus Digital Pathology
Free tierNo / unverifiedNo / unverified
HIPAANo / unverifiedNo / unverified
SOC 2 Type IINo / unverifiedNo / unverified
EHR integrationsNot specifiedNot specified
Founded2015n/a
HQTWUS

Scroll horizontally to see both columns.

Common questions

Open the full pathology comparison

Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.